The Alliance for Patient Access (AfPA) is an American 501(c)(4) nonprofit organization based in Washington, D.C.
Organization
AfPA is a member organization of the Alliance for a Stronger FDA[1] and a partner of the National Foundation for Infectious Diseases (NFID).[2]
Funding
Associate members and financial supporters of AfPA as of January 2022 include:[3]
- AbbVie
- Acadia Pharmaceuticals
- Adamas
- Alnylam Pharmaceuticals
- Amgen
- AstraZeneca
- Atara
- Avanir
- Biogen
- Boehringer Ingelheim
- Bristol-Myers Squibb (BMS)
- Eli Lilly
- Flexion Therapeutics
- GlaxoSmithKline
- Horizon Therapeutics
- Ionis
- Johnson & Johnson
- Lundbeck
- Neurocrine
- Novo Nordisk
- Pear
- Pharmaceutical Research and Manufacturers of America (PhRMA)
- Revance
- Sanofi
- Sobi
- Sunovion
- Takeda Pharmaceuticals
- Teva Pharmaceuticals
- UCB
- Urovant
- Vertex Pharmaceuticals
External links
List of Members. (2022, March 4). Alliance for a Stronger FDA. http://archive.today/2022.07.08-045902/https://www.strengthenfda.org/members ↩︎
NFID Partner Organizations. (2022, January 6). National Foundation for Infectious Diseases. https://web.archive.org/web/20220716065253/https://www.nfid.org/partners/ ↩︎
Associate Members and Financial Supporters. (2022, January). Alliance for Patient Access. https://web.archive.org/web/20220128105843/https://admin.allianceforpatientaccess.org/wp-content/uploads/2022/01/AfPADonorsJanuary2022.pdf ↩︎
